Published in Immunity on October 29, 2009
Immunity, inflammation, and cancer. Cell (2010) 28.27
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 3.57
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth (2013) 2.70
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med (2013) 2.50
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
Mechanistic links between COPD and lung cancer. Nat Rev Cancer (2013) 2.28
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol (2010) 2.12
Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med (2012) 2.11
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood (2010) 2.01
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Essentials of Th17 cell commitment and plasticity. Blood (2013) 1.95
A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood (2011) 1.84
IL-17RA signaling reduces inflammation and mortality during Trypanosoma cruzi infection by recruiting suppressive IL-10-producing neutrophils. PLoS Pathog (2012) 1.84
Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci (2011) 1.84
Th9 cells promote antitumor immune responses in vivo. J Clin Invest (2012) 1.80
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood (2010) 1.79
IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev (2010) 1.76
Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci U S A (2010) 1.73
IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol (2013) 1.65
Th17 cells in cancer: help or hindrance? Carcinogenesis (2011) 1.63
The Th17 family: flexibility follows function. Immunol Rev (2013) 1.58
Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One (2011) 1.56
Interleukin-17 and its expanding biological functions. Cell Mol Immunol (2010) 1.55
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol (2013) 1.53
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother (2012) 1.47
IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res (2010) 1.45
Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res (2013) 1.42
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A (2010) 1.36
T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A (2014) 1.36
Th17 cells in cancer: the ultimate identity crisis. Front Immunol (2014) 1.33
Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene (2010) 1.32
CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun (2011) 1.32
The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology (2012) 1.26
TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov (2011) 1.26
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer Microenviron (2014) 1.24
Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol (2013) 1.17
Concomitant activation and antigen uptake via human dectin-1 results in potent antigen-specific CD8+ T cell responses. J Immunol (2010) 1.16
The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One (2011) 1.15
Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res (2010) 1.14
Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J Clin Invest (2014) 1.13
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
Engineered T cells for anti-cancer therapy. Curr Opin Immunol (2012) 1.12
IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int (2011) 1.10
The role and regulation of human Th17 cells in tumor immunity. Am J Pathol (2012) 1.09
A protective role by interleukin-17F in colon tumorigenesis. PLoS One (2012) 1.08
Genetic controls of Th17 cell differentiation and plasticity. Exp Mol Med (2011) 1.05
Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol (2012) 1.03
Th17 cells and Tregs: unlikely allies. J Leukoc Biol (2014) 1.03
Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS One (2012) 1.02
Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood (2012) 1.02
A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology (2014) 1.01
Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLoS Pathog (2012) 1.01
Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol (2012) 1.01
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med (2013) 1.01
IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS One (2012) 1.01
Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol (2013) 1.00
A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun (2011) 1.00
Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci U S A (2014) 1.00
Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med (2013) 0.99
Home sweet home: the tumor microenvironment as a haven for regulatory T cells. Front Immunol (2013) 0.99
Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res (2010) 0.99
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells. Oncoimmunology (2013) 0.99
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol (2012) 0.99
The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm (2014) 0.98
CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism. J Immunol (2011) 0.98
Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1. J Immunol (2014) 0.97
Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J Immunol (2013) 0.96
Chronic dry eye disease is principally mediated by effector memory Th17 cells. Mucosal Immunol (2013) 0.95
Detection and significance of TregFoxP3(+) and Th17 cells in peripheral blood of non-small cell lung cancer patients. Arch Med Sci (2014) 0.95
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice. PLoS One (2013) 0.95
Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol (2012) 0.92
Noncanonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. J Immunol (2011) 0.92
Activated IL-23/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients. BMC Immunol (2011) 0.92
NFAT1 supports tumor-induced anergy of CD4(+) T cells. Cancer Res (2012) 0.91
Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction. Aging Cell (2011) 0.90
Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage? Expert Opin Biol Ther (2011) 0.90
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol (2012) 0.89
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88
CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets (2010) 0.88
Th17 Cell Plasticity and Functions in Cancer Immunity. Biomed Res Int (2015) 0.88
Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. Proc Natl Acad Sci U S A (2012) 0.88
Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer. World J Gastroenterol (2012) 0.88
Transcriptional profiling of disease-induced host responses in bovine tuberculosis and the identification of potential diagnostic biomarkers. PLoS One (2012) 0.87
Promotion of lung tumor growth by interleukin-17. Am J Physiol Lung Cell Mol Physiol (2014) 0.87
IEX-1 deficiency protects against colonic cancer. Mol Cancer Res (2012) 0.87
CD4 responses against IDO. Oncoimmunology (2012) 0.86
Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. PLoS One (2011) 0.86
Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J Biol Chem (2010) 0.86
TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone. J Drugs Dermatol (2010) 0.86
Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study. PLoS One (2013) 0.86
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature (2007) 14.28
Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity (2008) 10.26
Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (2003) 10.22
Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol (2003) 10.21
TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol (2008) 8.95
Differential antigen processing by dendritic cell subsets in vivo. Science (2007) 8.42
Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity (2009) 6.87
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol (2009) 6.74
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56
Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol (2001) 4.56
CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol (2000) 4.41
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol (2008) 3.51
Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol (2009) 3.42
Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res (2006) 3.41
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A (2006) 3.19
Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17
Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem (2006) 3.16
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A (2004) 2.70
A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res (2007) 2.50
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res (2007) 2.38
Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A (2008) 2.33
Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med (2002) 2.32
The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun (2008) 2.12
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res (2004) 1.74
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol (2008) 1.61
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J Immunol (2009) 1.54
Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest (2004) 1.44
Adoptive cell transfer therapy. Semin Oncol (2007) 1.44
Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res (2006) 1.42
Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol (2003) 1.40
The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr Opin Investig Drugs (2009) 1.36
Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg (1997) 0.97
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature (2007) 14.28
T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity (2007) 13.29
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem (2007) 10.41
Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity (2008) 10.26
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity (2008) 9.61
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Bcl6 mediates the development of T follicular helper cells. Science (2009) 8.50
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity (2009) 6.87
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Regulation of inflammatory responses by IL-17F. J Exp Med (2008) 5.56
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60
Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med (2011) 4.50
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol (2004) 4.43
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med (2007) 3.91
The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol (2006) 3.76
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69
IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med (2007) 3.66
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol (2008) 3.51
Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol (2009) 3.42
Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res (2006) 3.41
ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med (2008) 3.39
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol (2005) 3.23
B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity (2003) 3.18
Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem (2006) 3.16
Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. J Biol Chem (2007) 3.14
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest (2007) 3.02
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol (2005) 2.97
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity (2010) 2.90
Characterization of mouse and human B7-H3 genes. J Immunol (2002) 2.86
Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med (2013) 2.65
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64